References
- Marshall J . Conference scene: fighting a smarter war against cancer. Colorectal Cancer3, 131–133 (2014).
- Georgetown Lombardi Comprehensive Cancer Center. https://ruesch.georgetown.edu.
- Morse MA , NiedzwieckiD, MarshallJLet al. A randomized Phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann. Surg.258, 879–886 (2013).
- Schlom J . Therapeutic cancer vaccines: current status and moving forward. J. Natl Cancer Inst.104, 599–613 (2012).
- Chen DS , MellmanI. Oncology meets immunology: the cancer-immunity cycle. Immunity39, 1–10 (2013).
- Chen G , GuptaR, PetrikSet al. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol. Res.2, 949–961 (2014).
- Galon J , CostesA, Sanchez-CaboFet al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science313, 1960–1964 (2006).
- Galon J , MlecnikB, BindeaGet al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J. Pathol.232, 199–209 (2014).
- Ribas A , HerseyP, MiddletonMRet al. New challenges in endpoints for drug development in advanced melanoma. Clin. Cancer Res.18, 336–341 (2012).
- Georgetown Lombardi Comprehensive Cancer Center, Schafer Memorial Lecture. https://ruesch.georgetown.edu/about/symposium/schafer_lecture.
- Winslow R . Cancer's super-survivors – how the promise of immunotherapy is transforming oncology. Wall Street Journal4 December 2014.
- Couzin-Frankel J . Cancer immunotherapy. Science342, 1432–1433 (2013).
- Onclive. New paradigms emerge for translating immunotherapy into broad clinical use. www.onclive.com/publications/Oncology-live/2014/February-2014/New-Paradigms-Emerge-for-Translating-Immunotherapy-Into-Broad-Clinical-Use.
- Alexandrov LB , Nik-ZainalS, WedgeDCet al. Signatures of mutational processes in human cancer. Nature500, 415–421 (2013).
- Herbst RS , SoriaJC, KowanetzMet al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature515, 563–567 (2014).
- Hilton T , HulettT, DubayCet al. DPV-001 an autophagosome-enriched cancer vaccine in Phase II clinical trials contains 25 putative cancer antigens, DAMPS, HSPS and agonists for TLR 2, 3, 4, 7 and 9. J. Immunother. Cancer1, P260 (2013).
- Schlom J . Therapeutic cancer vaccines. Adv. Cancer Res.121, 67–124 (2014).
- Center For Cancer Research, Jeffrey Schlom . https://ccr.cancer.gov/jeffrey-schlom.
- Hamilton DH , LitzingerMT, JalesAet al. Immunological targeting of tumor cells undergoing an epithelial–mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget4, 1777–1790 (2013).
- Le DT , Wang-GillamA, PicozziVet al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J. Clin. Oncol. pii:JCO.2014.57.4244 (2015) ( Epub ahead of print).
- Wolchok JD , KlugerH, CallahanMKet al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med.369, 122–133 (2013).